



Project Name: Development of First-in-Class PD-1 Enhanced Nucleic Acid Vaccine Technology Platform and Therapeutic Nucleic Acid Vaccine

First in Class


Principal Investigator: Prof Zhiwei Chen



Significantly enhanced T cell responses



High immune response rate



Phase I clinical trial results: good immunogenicity
→ entering Phase 2a in 2026

- A single vaccine achieves 75% immunogenicity in human.
- Achieving long-term suppression of HIV without cocktail therapy and achieving functional cure.

Intellectual Property:
2 US, 1 EP and 3 CN active patents

Team Leader (PIC)
Prof. Zhiwei Chen
Tel: +852 39179825
Email: zchenai@hku.hk



The first multi-site Phase II
Clinical Trial at GBAICTI, Bay
Trial